These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 30236958

  • 1. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
    Skarp KP, Shams A, Montelin H, Lagerbäck P, Tängdén T.
    Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
    [Abstract] [Full Text] [Related]

  • 2. A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam.
    Birgy A, Delecourt M, Geslain G, Desselas E, Caseris M, Magnan M, Mariani-Kurkdjian P, Bidet P, Bonacorsi S.
    J Antimicrob Chemother; 2017 Jul 01; 72(7):1911-1914. PubMed ID: 28369441
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases.
    Marre R, Schulz E.
    Arzneimittelforschung; 1988 Jul 01; 38(7):863-5. PubMed ID: 3061383
    [Abstract] [Full Text] [Related]

  • 4. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Lampri N, Galani I, Poulakou G, Katsarolis I, Petrikkos G, Giamarellou H, Souli M.
    J Antimicrob Chemother; 2012 Oct 01; 67(10):2424-8. PubMed ID: 22665388
    [Abstract] [Full Text] [Related]

  • 5. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A.
    Clin Microbiol Infect; 2010 Feb 01; 16(2):132-6. PubMed ID: 19614715
    [Abstract] [Full Text] [Related]

  • 6. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
    Rossi B, Soubirou JF, Chau F, Massias L, Dion S, Lepeule R, Fantin B, Lefort A.
    Antimicrob Agents Chemother; 2016 Jan 01; 60(1):424-30. PubMed ID: 26525800
    [Abstract] [Full Text] [Related]

  • 7. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
    O'Kelly F, Kavanagh S, Manecksha R, Thornhill J, Fennell JP.
    BMC Infect Dis; 2016 Nov 03; 16(1):620. PubMed ID: 27806687
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.
    Torrico M, Aguilar L, González N, Giménez MJ, Echeverría O, Cafini F, Sevillano D, Alou L, Coronel P, Prieto J.
    Antimicrob Agents Chemother; 2007 Oct 03; 51(10):3699-706. PubMed ID: 17664320
    [Abstract] [Full Text] [Related]

  • 10. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.
    Cohen Stuart J, Leverstein-Van Hall M, Kortmann W, Verlind J, Mulder F, Scharringa J, Fluit A, Ekkelenkamp M.
    Eur J Clin Microbiol Infect Dis; 2018 Oct 03; 37(10):2021-2025. PubMed ID: 30117050
    [Abstract] [Full Text] [Related]

  • 11. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
    Søraas A, Sundsfjord A, Jørgensen SB, Liestøl K, Jenum PA.
    PLoS One; 2014 Oct 03; 9(1):e85889. PubMed ID: 24454943
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synergistic in vitro activity between aztreonam and amoxicillin-clavulanate against Enterobacteriaceae-producing class B and/or class D carbapenemases with or without extended-spectrum β-lactamases.
    Ract P, Compain F, Robin F, Decre D, Gallah S, Podglajen I.
    J Med Microbiol; 2019 Sep 03; 68(9):1292-1298. PubMed ID: 31361213
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Activity of mecillinam against AmpC beta-lactamase-producing Escherichia coli.
    Brenwald NP, Andrews J, Fraise AP.
    J Antimicrob Chemother; 2006 Jul 03; 58(1):223-4. PubMed ID: 16698846
    [No Abstract] [Full Text] [Related]

  • 16. In Vitro and In Vivo Activity of Amoxicillin-Clavulanate Combined with Ceftibuten or Cefpodoxime Against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae.
    Gupta A, Malik S, Kaminski M, Landman D, Quale JM.
    Microb Drug Resist; 2022 Apr 03; 28(4):419-424. PubMed ID: 35451880
    [Abstract] [Full Text] [Related]

  • 17. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez-Herrera J, Rodríguez-Baño J, Pascual A, Pachón J.
    Antimicrob Agents Chemother; 2013 May 03; 57(5):2109-13. PubMed ID: 23439636
    [Abstract] [Full Text] [Related]

  • 18. In vitro susceptibility to mecillinam of Escherichia coli strains isolated from the urine of pregnant women.
    Duployez C, Loiez C, Cattoen C, Descamps D, Wallet F, Vachée A, Microbiologist Network from Nord-Pas-de-CalaisRéseau de microbiologistes du Nord-Pas-de-Calais, Nord-Pas-de-Calais, France..
    Med Mal Infect; 2016 Dec 03; 46(8):436-441. PubMed ID: 27609597
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections.
    Birgy A, Madhi F, Jung C, Levy C, Cointe A, Bidet P, Hobson CA, Bechet S, Sobral E, Vuthien H, Ferroni A, Aberrane S, Cuzon G, Beraud L, Gajdos V, Launay E, Pinquier D, Haas H, Desmarest M, Dommergues MA, Cohen R, Bonacorsi S, Group of the National Observatory of Urinary tract Infection due to ESBL-producing Enterobacteriaceae in children.
    J Antimicrob Chemother; 2021 Oct 11; 76(11):2839-2846. PubMed ID: 34453533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.